68001-541 : Bortezomib 3.5 mg/3.5ml Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution


NDC: 68001-541
Labeler: Bluepoint Laboratories
Product Type: Human Prescription Drug
Drug Name:  Bortezomib
Dosage Form: Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution
Application #: ANDA209622
Rev. Date: 


NDC Package Codes:

  • 68001-541-36: 1 VIAL, SINGLE‑USE IN 1 CARTON (68001‑541‑36) > 3.5 ML IN 1 VIAL, SINGLE‑USE

Active Ingredients:

  • Bortezomib

Dosage Strength:

  • 3.5 mg/3.5mL

Pharmaceutical Classes:

  • Proteasome Inhibitor [EPC]
  • Proteasome Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 68001-534 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Bluepoint Laboratories
  • 68001-540 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Bluepoint Laboratories
  • 0143-9098 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Hikma Pharmaceuticals USA Inc.
  • 0409-1700 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Hospira, Inc.
  • 0409-1703 Bortezomib 2.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Hospira, Inc.
  • 0409-1704 Bortezomib 1 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Hospira, Inc.
  • 0781-3258 Bortezomib 3.5 mg Intravenous Injection, Powder, Lyophilized, for Solution by Sandoz Inc
  • 10019-991 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Baxter Healthcare Corporation
  • 25021-244 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Sagent Pharmaceuticals
  • 43598-426 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Dr.reddy's Laboratories, Inc.
  • 43598-865 Bortezomib 3.5 mg Intravenous Injection, Powder, Lyophilized, for Solution by Dr.reddy's Laboratories Inc
  • 50742-484 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Ingenus Pharmaceuticals, LLC
  • 51817-586 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Pharmascience Inc.
  • 55150-337 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Auromedics Pharma LLC
  • 60505-6050 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Apotex Corp
  • 63323-721 Bortezomib 1 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Fresenius Kabi USA, LLC
  • 63323-821 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Fresenius Kabi USA, LLC
  • 67184-0530 Bortezomib 3.5 mg Intravenous; Subcutaneous Injection, Powder, Lyophilized, for Solution by Qilu Pharmaceutical Co., Ltd.
  • 70511-161 Bortezomib 1 mg Intravenous Injection by Maia Pharmaceuticals, Inc.
  • 70511-162 Bortezomib 2.5 mg Intravenous Injection by Maia Pharmaceuticals, Inc.
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 68001-541 QR Code

< Prev: 68001-540Next: 68001-542 >

Related Discussions:

gabantin-Bortezomib induced peripheral neuropathy(BINP)
I am a multiple myeloma patient, undergone 3 cycles of chemotherapy with bortezomib,and undergone autologus bonemarrow t... 1 reply




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.